Foresite Capital Management III’s Ascendis Pharma A/S ASND Stock Holding History

Foresite Capital Management III’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$13.8M	Hold	133,691	–	–	36.44%	1
2022 Q2	$12.4M	Hold	133,691	–	–	45.08%	1
2022 Q1	$15.7M	Hold	133,691	–	–	47.81%	1
2021 Q4	$18M	Buy	+133,691	New	+$19.9M	45.53%	1
2020 Q1	–	Sell	-13,922	Closed	-$1.94M	–	10
2019 Q4	$1.94M	Sell	13,922 -190,166	-93%	-$21.1M	1.09%	10
2019 Q3	$19.7M	Hold	204,088	–	–	7.51%	5
2019 Q2	$23.5M	Hold	204,088	–	–	7.71%	5
2019 Q1	$24M	Hold	204,088	–	–	6.25%	5
2018 Q4	$12.8M	Buy	204,088 +12,500	+7%	+$785K	4.2%	8
2018 Q3	$13.6M	Hold	191,588	–	–	3%	10
2018 Q2	$12.7M	Sell	191,588 -110,421	-37%	-$7.26M	2.74%	12
2018 Q1	$19.8M	Sell	302,009 -34,255	-10%	-$1.93M	4.3%	9
2017 Q4	$13.5M	Buy	336,264 +51,121	+18%	+$1.86M	3.78%	7
2017 Q3	$10.3M	Buy	285,143 +262,743	+1,173%	+$7.54M	2.85%	11
2017 Q2	$622K	Sell	22,400 -77,600	-78%	-$2.05M	0.2%	23
2017 Q1	$2.8M	Sell	100,000 -80,000	-44%	-$2.02M	1.07%	15
2016 Q4	$3.64M	Buy	+180,000	New	+$3.6M	1.58%	14

Other funds holding ASND

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Foresite Capital Management III's ASND Position: Q3 2022 in Review

Foresite Capital Management III held its Ascendis Pharma A/S (ASND) position steady in Q3 2022 at 133,691 shares worth $13.8M. The position accounts for 36.44% of the portfolio, ranked #1.

Foresite Capital Management III first reported a position in ASND in Q4 2016 and has held it in 17 quarters since. The position peaked at $24M in Q1 2019. 183 funds tracked by Wall St. Rank hold ASND as of Q3 2022.

Foresite Capital Management III held 133,691 shares of Ascendis Pharma A/S worth $13.8M as of Q3 2022.
Foresite Capital Management III left its Ascendis Pharma A/S share count unchanged in Q3 2022.
Ascendis Pharma A/S made up 36.44% of Foresite Capital Management III's portfolio in Q3 2022, its #1 holding.
Foresite Capital Management III first reported a position in Ascendis Pharma A/S in Q4 2016 and has held it in 17 quarters since.
Foresite Capital Management III's Ascendis Pharma A/S position peaked at $24M in Q1 2019.
183 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2022.

Based on Foresite Capital Management III's 13F filing for Q3 2022, filed 14 Nov 2022.